Ñî¹óåú´«Ã½Ò•îl

Two new randomized, controlled trials published yesterday in the Annals of Internal Medicine describe how drug combinations lowered the risk of severe COVID-19, with one detailing use of the antidepressant fluvoxamine plus the corticosteroid budesonide, and the other outlining the monoclonal antibody duo amubarvimab plus romlusevimab. (Van Beusekom, 4/18)

JAMA Network Open has published a new US national cohort study demonstrating that early administration of the steroid dexamethasone was associated with significantly reduced odds of mortality or discharge to hospice in those requiring supplemental oxygen or mechanical ventilation and/or extracorporeal membrane oxygenation. (Soucheray, 4/18)

AbbVie’s Qulipta has gained an edge in the heated migraine market thanks to a new approval to prevent chronic migraines. (Becker, 4/18)

The U.S. Food and Drug Administration said on Monday it had approved the use of Gamida Cell Ltd's cell therapy for cutting the risk of infection in patients undergoing treatment for blood cancer, sending the company's shares up 46%. (4/17)

A panel of U.S. Food and Drug Administration advisers on Monday unanimously voted in favor of Innoviva Inc's (INVA.O) experimental antibiotic in the treatment of serious bacterial infections, typically associated with hospitalizations, the company said. (Mahobe and Roy, 4/17)

Eli Lilly and Co said on Thursday that the U.S. Food and Drug Administration (FDA) had declined to approve its drug to treat a type of chronic inflammatory bowel disease in adults. (4/13)

In a paper recently published in Advanced Science, Houston Methodist Research Institute researchers used an implantable nanofluidic device they invented to deliver CD40 monoclonal antibodies (mAb), a promising immunotherapeutic agent, at a sustained low-dose via the nanofluidic drug-eluting seed (NDES). (Houston Methodist, 4/13)